2015
High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma
Damast S, Higgins SA, Ratner E, De Leon MC, Mani S, Silasi DA, Azodi M, Santin A, Rutherford T, Schwartz PE. High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. Journal Of Contemporary Brachytherapy 2015, 7: 35-40. PMID: 25829935, PMCID: PMC4371058, DOI: 10.5114/jcb.2015.48539.Peer-Reviewed Original ResearchRecurrence-free survivalUterine serous carcinomaComprehensive surgical stagingOverall survivalSurgical stagingSerous carcinomaPara-aortic lymph node dissectionFIGO 2009 stage ICarboplatin-paclitaxel chemotherapyInstitutional chart reviewIsolated vaginal recurrencesSimultaneous lung metastasisLymph node dissectionPelvic control rateKaplan-Meier methodRate vaginal brachytherapyCases of recurrenceMedian followNode dissectionPeritoneal cytologyVaginal brachytherapyVaginal recurrenceTotal hysterectomyChart reviewBrachytherapy dose
2013
Breast conservation therapy for ductal carcinoma in situ (DCIS): does presentation of disease affect long-term outcomes?
Bai HX, Motwani SB, Higgins SA, Haffty BG, Wilson LD, Lannin DR, Evans SB, Moran MS. Breast conservation therapy for ductal carcinoma in situ (DCIS): does presentation of disease affect long-term outcomes? International Journal Of Clinical Oncology 2013, 19: 460-466. PMID: 23780727, DOI: 10.1007/s10147-013-0575-0.Peer-Reviewed Original ResearchConceptsBreast conservation treatmentLocal relapse-free survivalRelapse-free survivalSigns/symptomsLong-term outcomesDCIS patientsPhysical signs/symptomsTumor sizeER/PR/HERWorse long-term prognosisSignificant overall survival differenceAdjuvant hormone treatmentLong-term prognosisOverall survival differenceBreast conservation therapyLarger tumor sizeStatus of marginsNon-white racePresentation of diseaseMedian followClinicopathological differencesNodal involvementOverall survivalIndependent predictorsConservation therapy